Skip to main content
. 2018 Jan 14;24(2):226–236. doi: 10.3748/wjg.v24.i2.226

Figure 4.

Figure 4

FNAR1 is a direct target of miR-93-5p . A: The binding sites for miR-93-5p in the IFNAR1 3’-UTR, and the design of mutant binding sites in the IFNAR1 3’-UTR for miR-93-5p; B: Luciferase assay shows that miR-93-5p agomir inhibits the relative luciferase activity in the binding site 1 or 2-expressing HEK293T cells, but not in the binding site 3- or mutant binding sites-expressing HEK293T cells. This experiment was repeated six times; C and D: Western blot shows the protein expression of IFNAR1 in Huh7 cells transfected with ago-NC (200 nmol/L), miR-93-5p agomir (200 nmol/L), anta-NC (200 nmol/L), and miR-93-5p antagomir (200 nmol/L). This experiment was repeated twice; E: qRT-PCR shows the mRNA expression of IFNAR1 in Huh7 cells transfected with ago-NC (200 nmol/L), miR-93-5p agomir (200 nmol/L), anta-NC (200 nmol/L), and miR-93-5p antagomir (200 nmol/L). β-actin was used as an internal reference. This experiment was repeated three times. IFNAR1: Interferon receptor 1.